1. Cell Biology
  2. Developmental Biology

Reversal of β cell de-differentiation by a small molecule inhibitor of the TGFβ pathway

  1. Barak Blum
  2. Adam N Roose
  3. Ornella Barrandon
  4. René Maehr
  5. Anthony C Arvanites
  6. Lance S Davidow
  7. Jeffrey C Davis
  8. Quinn P Peterson
  9. Lee L Rubin
  10. Douglas A Melton  Is a corresponding author
  1. Harvard Stem Cell Institute, Harvard University, United States
  2. University of Massachusetts Medical School, United States
https://doi.org/10.7554/eLife.02809
Share this article
Cite this article
  1. Barak Blum
  2. Adam N Roose
  3. Ornella Barrandon
  4. René Maehr
  5. Anthony C Arvanites
  6. Lance S Davidow
  7. Jeffrey C Davis
  8. Quinn P Peterson
  9. Lee L Rubin
  10. Douglas A Melton
(2014)
Reversal of β cell de-differentiation by a small molecule inhibitor of the TGFβ pathway
eLife 3:e02809.
https://doi.org/10.7554/eLife.02809
  2. Download BibTeX
  3. Download .RIS

Abstract

Dysfunction or death of pancreatic β cells underlies both types of diabetes. This functional decline begins with β cell stress and de-differentiation. Current drugs for T2D lower blood glucose levels, but they do not directly alleviate β cell stress nor prevent, let alone reverse, β cell de-differentiation. We show here that Urocortin 3 (Ucn3), a marker for mature β cells, is down-regulated in the early stages of T2D in mice and when β cells are stressed in vitro. Using an insulin expression-coupled lineage tracer, with Ucn3 as a reporter for the mature β cell state, we screen for factors that reverse β cell de-differentiation. We find that a small molecule inhibitor of TGFβ receptor I (Alk5) protects cells from the loss of key β cell transcription factors and restores a mature β cell identity even after exposure to prolonged and severe diabetes.

Article and author information

Author details

  1. Barak Blum

    Harvard Stem Cell Institute, Harvard University, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Adam N Roose

    Harvard Stem Cell Institute, Harvard University, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Ornella Barrandon

    Harvard Stem Cell Institute, Harvard University, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. René Maehr

    University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Anthony C Arvanites

    Harvard Stem Cell Institute, Harvard University, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Lance S Davidow

    Harvard Stem Cell Institute, Harvard University, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Jeffrey C Davis

    Harvard Stem Cell Institute, Harvard University, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Quinn P Peterson

    Harvard Stem Cell Institute, Harvard University, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. Lee L Rubin

    Harvard Stem Cell Institute, Harvard University, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.

  10. Douglas A Melton

    Harvard Stem Cell Institute, Harvard University, Cambridge, United States
    For correspondence
    dmelton@harvard.edu
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: Animal experiments were performed in compliance with the Harvard University International Animal Care and Use Committee (IACUC) guidelines (protocol #93-15).

Human subjects: Institutional review board approval for research use of human tissue was obtained from the Harvard University Faculty of Arts and Sciences. Human islets were obtained from NDRI (The National Disease Research Interchange). Donor anonymity was preserved, and the human tissue was collected under applicable regulations and guidelines regarding consent, protection of human subjects and donor confidentiality

Copyright

© 2014, Blum et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,986
    views
  • 930
    downloads
  • 117
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Barak Blum
  2. Adam N Roose
  3. Ornella Barrandon
  4. René Maehr
  5. Anthony C Arvanites
  6. Lance S Davidow
  7. Jeffrey C Davis
  8. Quinn P Peterson
  9. Lee L Rubin
  10. Douglas A Melton
(2014)
Reversal of β cell de-differentiation by a small molecule inhibitor of the TGFβ pathway
eLife 3:e02809.
https://doi.org/10.7554/eLife.02809

Share this article

https://doi.org/10.7554/eLife.02809

Categories and tags

Research organisms

Further reading

    1. Cell Biology

    Small-molecule activation of TFEB alleviates Niemann–Pick disease type C via promoting lysosomal exocytosis and biogenesis

    Kaili Du, Hongyu Chen ... Dan Li
    Research Article

    Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.

    1. Cell Biology

    Stratification of enterochromaffin cells by single-cell expression analysis

    Yan Song, Linda J Fothergill ... Gene W Yeo
    Research Article

    Dynamic interactions between gut mucosal cells and the external environment are essential to maintain gut homeostasis. Enterochromaffin (EC) cells transduce both chemical and mechanical signals and produce 5-hydroxytryptamine to mediate disparate physiological responses. However, the molecular and cellular basis for functional diversity of ECs remains to be adequately defined. Here, we integrated single-cell transcriptomics with spatial image analysis to identify 14 EC clusters that are topographically organized along the gut. Subtypes predicted to be sensitive to the chemical environment and mechanical forces were identified that express distinct transcription factors and hormones. A Piezo2+ population in the distal colon was endowed with a distinctive neuronal signature. Using a combination of genetic, chemogenetic, and pharmacological approaches, we demonstrated Piezo2+ ECs are required for normal colon motility. Our study constructs a molecular map for ECs and offers a framework for deconvoluting EC cells with pleiotropic functions.

    1. Cell Biology
    2. Developmental Biology

    Lens Development: Bringing signaling complexity into focus

    Sarah Y Coomson, Salil A Lachke
    Insight

    A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.